Take in Non-CME Industry Symposia at ATS 2015

Enrich your ATS 2015 International Conference experience by participating in Non-CME Industry Symposia. (Photo: R.C. Photographic Productions)

The ATS encourages Non-CME Industry Symposia in conjunction with the International Conference. All full-conference participants are encouraged to attend these programs.


6:30 to 9 p.m.
Sheraton Denver Downtown: Plaza Ballroom ABC (Plaza Building; Concourse Level)
Advances in the Management of Idiopathic Pulmonary Fibrosis

6:30 to 7 p.m.: Registration and Dinner
7 to 9 p.m.: Interactive Non-CME Symposia

Until recently, the only option for patients with idiopathic pulmonary fibrosis was transplant surgery. New pharmaceutical agents offer clinicians several therapies for managing this devastating, fatal disease. In this interactive dinner symposium, leading clinicians will discuss treatments and present cases that allow attendees to manage patients and compare their strategies.

Company: Vindico Medical Education Supported by a grant from Genentech, Inc.

6:30 to 9:30 p.m.
Grand Hyatt Denver: Imperial Ballroom (2nd Floor)
Co-Suspension Technology: Opening up New Possibilities for Inhaled Drug

This symposium offers an opportunity to learn more about the science of phospholipid co-suspension technology and its use for the delivery of inhaled respiratory medication.

Speakers: Gary Ferguson, Michigan; Anthony Hickey, North Carolina; Sarvajna Dwivedi, Pearl/AstraZeneca; and Chet Leach, Pearl/AstraZeneca

Company: AstraZeneca Pharmaceuticals, Inc.

6:30 to 9:30 p.m.
Sheraton Denver Downtown: Plaza Ballroom DEF (Plaza Building; Concourse Level)
Expert Perspectives: A Hands”on Look at a Changing PAH Landscape

Company: Actelion Pharmaceuticals US, Inc.

6:30 to 9:30 p.m.
Embassy Suites Denver-Downtown Convention Center: Crystal Ballroom (3rd Floor)
Selection of Long-Term Maintenance Therapy for Patients with COPD

Engage with a panel of experts who will discuss the selection of long-term maintenance bronchodilator therapy in patients with COPD. The session will provide an interactive forum and promises to be engaging for all participants.

Company: Boehringer Ingelheim Pharmaceuticals, Inc.

6:30 to 9:30 p.m.
Embassy Suites Denver-Downtown Convention Center: Silverton Ballroom (2nd Floor)
Translating IPF Clinical Trials to Real Life Patients

Care of patients with IPF has been transformed since the 2014 FDA approval of pirfenidone and nintedanib for the treatment of patients with IPF. Furthermore, clinical results from the ASCEND, INPULSIS, and PANTHER trials have raised many questions in the treatment of these patients. Providers considering these drugs for their patients face decisions of which drug is best for an individual patient, when to start, switch or combine treatments, and how to manage side effects and dosing. This case based symposium will explore real-world issues of treating patients with IPF.

Speakers: Luca Richeldi, MD, PhD (Chair), Professor of Respiratory Medicine, Chair of Interstitial Lung Disease, University of Southampton, Southampton, UK; Kevin K. Brown, MD, Professor of Medicine, Department of Medicine, Vice Chair, Department of Medicine Clinical Affairs, National Jewish Health, Denver, CO; Harold R. Collard, Associate Professor of Medicine, Director, Interstitial Lung Disease Program, University of California San Francisco, San Francisco, CA; and Marilyn K.  Glassberg, MD, Professor of Medicine and Surgery, Director, Interstitial Lung Disease Program, Miller School of Medicine, Miami, FL

Company: The France Foundation (supported by a grant from Boehringer Ingelheim Pharmaceuticals, Inc.)